Cancer Immunotherapy News and Research

RSS

Research paves way for development of individualized immunotherapy for treating cancer

Mainz-based researchers have made significant advances with regard to the development of individualized immunotherapy strategies for treating cancer. They have managed to identify the relevant genetic changes or mutations associated with various types of cancer and have determined their individual blueprints.

13 May 2015

Invectys begins INVAC-1 phase I clinical trial in cancer patients

Invectys announces today that it has initiated a phase I clinical trial of its immunotherapeutic drug candidate INVAC-1.

13 May 2015

Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Dana-Farber/Boston Children's Cancer and Blood Disorders Center has joined a clinical trial of immunotherapy for children with relapsed or treatment-resistant acute lymphoblastic leukemia (ALL). Led by Memorial Sloan Kettering Cancer Center, the trial is one of several nationally that are evaluating cancer immunotherapy, a treatment approach -- hailed by Science magazine as their Breakthrough of the Year in 2013 -- that triggers a patient's immune system to attack his or her cancer cells.

11 May 2015

Sangamo BioSciences to present data on ZFP Therapeutic platform at ASGCT meeting

Sangamo BioSciences, Inc. announced that data from clinical, preclinical and research-stage programs focused on the development of ZFP Therapeutics will be presented at the 18th Annual Meeting of the American Society of Gene and Cell Therapy

29 Apr 2015

Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Astellas Pharma Inc. and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an exclusive research and development collaboration.

22 Apr 2015

Novel approach allows real-time imaging of ongoing immune response

A novel approach that allows real-time imaging of the immune system's response to the presence of tumors—without the need for blood draws or invasive biopsies—offers a potential breakthrough both in diagnostics and in the ability to monitor efficacy of cancer therapies.

21 Apr 2015

Pembrolizumab drug halts tumor growth in 76% of patients with pleural mesothelioma

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

20 Apr 2015

Penn professor to be recognized with AACR-CRI Lloyd J. Old Award in Cancer Immunology

The American Association for Cancer Research and the Cancer Research Institute will recognize Carl H. June, MD, the Richard W. Vague professor in immunotherapy at the Perelman School of Medicine and director of the Center for Cellular Immunotherapies at the University of Pennsylvania in Philadelphia, with the third annual AACR-CRI Lloyd J. Old Award in Cancer Immunology at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.

20 Apr 2015

James Allison to be honored with 2015 Pezcoller Foundation-AACR International Award for Cancer Research

The 2015 Pezcoller Foundation-American Association for Cancer Research (AACR) International Award for Cancer Research will be presented to James P. Allison, PhD, at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.

17 Apr 2015

CiRA, Takeda collaborate to develop clinical applications of iPS cells

Center for iPS Cell Research Application of Kyoto University and Takeda Pharmaceutical Company Limited announced today that they will work together to develop clinical applications of induced pluripotent stem cells in areas such as heart failure, diabetes mellitus, neurological disorders and cancer immunotherapy.

17 Apr 2015

MabVax closes $11.6 million in private placement

MabVax Therapeutics Holdings, Inc., a clinical-stage cancer immunotherapy company, is pleased to announce that it has closed on gross proceeds of approximately $11.6 million in a private placement (the "Private Placement") led by OPKO Health, Inc. and Dr. Phillip Frost, CEO and Chairman of OPKO Health.

6 Apr 2015

Personalized cancer vaccines can be used to marshal powerful immune response

Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis.

6 Apr 2015

Rigontec raises €4.8 million in second closing of Series A financing round

Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor.

24 Mar 2015

ImmunoCellular, PharmaCell sign manufacturing agreement for European production of ICT-107

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma (GBM).

19 Mar 2015

Physicians, researchers to discuss advances in cancer immunotherapies at UChicago symposium

The Ben May Department for Cancer Research at the University of Chicago will hold a day-long symposium on cancer immunotherapy for physicians and researchers.

18 Mar 2015

Penn researcher named a recipient of 2015 Paul Ehrlich and Ludwig Darmstaedter Prize

University of Pennsylvania cancer and HIV expert Carl June, MD, has been named one of two recipients of the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize for his outstanding work in cancer immunotherapy. Since 1952, the Paul Ehrlich and Ludwig Darmstaedter Prize has been awarded to scientists who have made great advancements in the fields in which Paul Ehrlich worked, in particular immunology, cancer research, microbiology, and chemotherapy.

12 Mar 2015

CPRIT awards research and recruitment grants to improve cancer research

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded UT Southwestern Medical Center researchers more than $7.5 million in research grants to improve diagnostic and therapeutic services and research relating to cancers of the brain, breast, throat, and bone, as well as to improve scientific understanding of cancer biology.

9 Mar 2015

New approach could dramatically increase survival rate of cancer patients

Michail Sitkovsky, an immunophysiology expert at Northeastern University, and his research colleagues have made a breakthrough discovery in cancer treatment. The new approach, some 30 years in the making, could dramatically increase the survival rate of patients with cancer, which kills some 8 million people each year.

5 Mar 2015

Crown Bioscience, NRCMM partner to develop new immune-oncology experimental cancer models

Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.

6 Feb 2015

Professor Jonathan Sprent named recipient of AAI Lifetime Achievement Award

The American Association of Immunologists has selected Professor Jonathan Sprent FAA FRS, from Sydney's Garvan Institute of Medical Research, to be the 2015 recipient of the AAI Lifetime Achievement Award.

23 Jan 2015